H3K18la is upregulated in activated HSCs, and either HSC-specific or systemic deletion of hexokinase 2 (HK2) inhibits hepatic fibrosis in vivo by reducing H3K18la expression, which is reversed by exogenously supplementing lactate (Rho et al., 2023). Here, HK2 is linked to Hepatic fibrosis.